This application represents a revised resubmission application for a Specialized Program of Research Excellence (SPORE) in Prostate Cancer from the Prostate Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE has been funded for two cycles since 2002. DF/HCC is comprised of the following institutions: Dana-Farber Cancer Institute;Harvard Medical School;Harvard School of Public Health;Beth Israel-Deaconess Medical Center;Brigham and Women's Hospital;Massachusetts General Hospital;and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Broad Institute and Massachusetts Institute of Technology are collaborating institutions in this grant. The DF/HCC Prostate Cancer SPORE has its administrative base at the DFCI. Dr. Philip Kantoff, who has led the DF/HCC Prostate Cancer Program and SPORE since their inception, is joined by Co-Directors Dr. William Hahn, a laboratory scientist at DFCI, and Dr. Steven Balk, a laboratory scientist at BIDMC. Dr. Kantoff reports directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Prostate Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 4 Projects which address critical problems in prostate cancer and have translational components including 1) understanding the mechanism by which obesity impacts prostate cancer mortality 2) dissecting the clinical heterogeneity of Gleason 7 prostate cancer 3) understanding the role that genomic change has on resistance to primary androgen deprivation therapy and on aggressive prostate cancer and finally 4) understanding the androgen receptor based mechanisms of resistance in castration resistant disease. The four projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue and Pathology Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future.
This SPORE is focused on several important themes in prostate cancer: 1) the identification of lethal prostate cancer using genetic and genomic approaches and 2) understanding the role of metabolism on the development of lethal prostate cancer, and understanding the mechanism of primary and secondary resistance to hormonal therapy and finally elucidating new targets for therapy in men with advanced disease.
|Dickerman, Barbra A; Ahearn, Thomas U; Giovannucci, Edward et al. (2017) Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer 141:933-944|
|Cacciatore, Stefano; Zadra, Giorgia; Bango, Clyde et al. (2017) Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues. Mol Cancer Res 15:439-447|
|Sinnott, Jennifer A; Peisch, Sam F; Tyekucheva, Svitlana et al. (2017) Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res 23:81-87|
|Zareba, Piotr; Flavin, Richard; Isikbay, Masis et al. (2017) Perineural Invasion and Risk of Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev 26:719-726|
|Han, W; Gao, S; Barrett, D et al. (2017) Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene :|
|McKay, Rana R; Werner, Lillian; Mostaghel, Elahe A et al. (2017) A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 23:935-945|
|Qu, Fangfang; Xie, Wanling; Nakabayashi, Mari et al. (2017) Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res 23:726-734|
|Graff, Rebecca E; Ahearn, Thomas U; Pettersson, Andreas et al. (2017) Height, obesity, and the risk of TMPRSS2:ERG-defined prostate cancer. Cancer Epidemiol Biomarkers Prev :|
|Liu, Xiaming; Gao, Yanfei; Ye, HuiHui et al. (2017) Positive feedback loop mediated by protein phosphatase 1? mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res 45:3738-3751|
|Tyekucheva, Svitlana; Bowden, Michaela; Bango, Clyde et al. (2017) Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun 8:420|
Showing the most recent 10 out of 240 publications